(Q38021967)

English

Acquired resistance mechanisms to tyrosine kinase inhibitors in lung cancer with activating epidermal growth factor receptor mutation--diversity, ductility, and destiny

scientific article published on December 2012

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

27 August 2017

Acquired resistance mechanisms to tyrosine kinase inhibitors in lung cancer with activating epidermal growth factor receptor mutation--diversity, ductility, and destiny (English)

1 reference

Europe PubMed Central

PubMed publication ID

27 August 2017

1 reference

based on heuristic

inferred from title

Tetsuya Mitsudomi

4

1 reference

Europe PubMed Central

PubMed publication ID

27 August 2017

Yoshihiko Maehara

3

object named as

Yoshihiko Maehara

1 reference

Europe PubMed Central

PubMed publication ID

27 August 2017

author name string

Kenichi Suda

1

1 reference

Europe PubMed Central

PubMed publication ID

27 August 2017

Hiroshi Mizuuchi

2

1 reference

Europe PubMed Central

PubMed publication ID

27 August 2017

publication date

1 December 2012

1 reference

Europe PubMed Central

PubMed publication ID

27 August 2017

Cancer and Metastasis Reviews

1 reference

Europe PubMed Central

PubMed publication ID

27 August 2017

31

1 reference

Europe PubMed Central

PubMed publication ID

27 August 2017

3-4

1 reference

Europe PubMed Central

PubMed publication ID

27 August 2017

807-814

1 reference

Europe PubMed Central

PubMed publication ID

27 August 2017

https://scigraph.springernature.com/pub.10.1007/s10555-012-9391-7

0 references

New driver mutations in non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9391-7

21 January 2018

Cancer. Addiction to oncogenes--the Achilles heal of cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9391-7

21 January 2018

Biological and clinical significance of KRAS mutations in lung cancer: an oncogenic driver that contrasts with EGFR mutation

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9391-7

21 January 2018

Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9391-7

21 January 2018

Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9391-7

21 January 2018

Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9391-7

21 January 2018

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9391-7

21 January 2018

Clinical definition of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9391-7

21 January 2018

EGFR mutation and resistance of non-small-cell lung cancer to gefitinib

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9391-7

21 January 2018

Mutation of threonine 766 in the epidermal growth factor receptor reveals a hotspot for resistance formation against selective tyrosine kinase inhibitors

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9391-7

21 January 2018

Rebiopsy of lung cancer patients with acquired resistance to EGFR inhibitors and enhanced detection of the T790M mutation using a locked nucleic acid-based assay

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9391-7

21 January 2018

The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9391-7

21 January 2018

Optimization of dosing for EGFR-mutant non-small cell lung cancer with evolutionary cancer modeling

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9391-7

21 January 2018

EGFR T790M mutation: a double role in lung cancer cell survival?

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9391-7

21 January 2018

Acquired resistance to EGFR tyrosine kinase inhibitors in EGFR-mutant lung cancer: distinct natural history of patients with tumors harboring the T790M mutation

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9391-7

21 January 2018

T790M is associated with a favorable prognosis in Japanese patients treated with an EGFR-TKI.

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9391-7

21 January 2018

Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor-mutant lung adenocarcinomas with acquired resistance to kinase inhibitors

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9391-7

21 January 2018

BIM mediates EGFR tyrosine kinase inhibitor-induced apoptosis in lung cancers with oncogenic EGFR mutations

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9391-7

21 January 2018

Acquired resistance to epidermal growth factor receptor kinase inhibitors associated with a novel T854A mutation in a patient with EGFR-mutant lung adenocarcinoma

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9391-7

21 January 2018

MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9391-7

21 January 2018

Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9391-7

21 January 2018

Activation of MET by gene amplification or by splice mutations deleting the juxtamembrane domain in primary resected lung cancers

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9391-7

21 January 2018

MET tyrosine kinase inhibitor crizotinib (PF-02341066) shows differential antitumor effects in non-small cell lung cancer according to MET alterations

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9391-7

21 January 2018

Loss of PTEN expression by blocking nuclear translocation of EGR1 in gefitinib-resistant lung cancer cells harboring epidermal growth factor receptor-activating mutations

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9391-7

21 January 2018

Conversion from the "oncogene addiction" to "drug addiction" by intensive inhibition of the EGFR and MET in lung cancer with activating EGFR mutation

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9391-7

21 January 2018

Expression of selected gene for acquired drug resistance to EGFR-TKI in lung adenocarcinoma.

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9391-7

21 January 2018

Amplification of CRKL induces transformation and epidermal growth factor receptor inhibitor resistance in human non-small cell lung cancers

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9391-7

21 January 2018

Hepatocyte growth factor induces gefitinib resistance of lung adenocarcinoma with epidermal growth factor receptor-activating mutations.

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9391-7

21 January 2018

Hepatocyte growth factor expression in EGFR mutant lung cancer with intrinsic and acquired resistance to tyrosine kinase inhibitors in a Japanese cohort.

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9391-7

21 January 2018

FAS and NF-κB signalling modulate dependence of lung cancers on mutant EGFR.

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9391-7

21 January 2018

High-throughput tissue microarray analysis used to evaluate biology and prognostic significance of the E-cadherin pathway in non-small-cell lung cancer.

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9391-7

21 January 2018

Twist, a master regulator of morphogenesis, plays an essential role in tumor metastasis

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9391-7

21 January 2018

Epithelial-mesenchymal transitions: twist in development and metastasis

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9391-7

21 January 2018

Clinical and molecular evidences of epithelial to mesenchymal transition in acquired resistance to EGFR-TKIs

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9391-7

21 January 2018

Epithelial to mesenchymal transition in an epidermal growth factor receptor-mutant lung cancer cell line with acquired resistance to erlotinib

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9391-7

21 January 2018

TGF-beta IL-6 axis mediates selective and adaptive mechanisms of resistance to molecular targeted therapy in lung cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9391-7

21 January 2018

Slug confers resistance to the epidermal growth factor receptor tyrosine kinase inhibitor

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9391-7

21 January 2018

Presence of epidermal growth factor receptor gene T790M mutation as a minor clone in non-small cell lung cancer.

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9391-7

21 January 2018

Detection of mutations in EGFR in circulating lung-cancer cells

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9391-7

21 January 2018

Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC.

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9391-7

21 January 2018

Reciprocal and complementary role of MET amplification and EGFR T790M mutation in acquired resistance to kinase inhibitors in lung cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9391-7

21 January 2018

Emergence of epidermal growth factor receptor T790M mutation during chronic exposure to gefitinib in a non small cell lung cancer cell line

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9391-7

21 January 2018

Amplification of EGFR T790M causes resistance to an irreversible EGFR inhibitor

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9391-7

21 January 2018

A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9391-7

21 January 2018

MET-independent lung cancer cells evading EGFR kinase inhibitors are therapeutically susceptible to BH3 mimetic agents

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9391-7

21 January 2018

A common BIM deletion polymorphism mediates intrinsic resistance and inferior responses to tyrosine kinase inhibitors in cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9391-7

21 January 2018

Effect of re-treatment with gefitinib ('Iressa', ZD1839) after acquisition of resistance

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9391-7

21 January 2018

EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors.

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9391-7

21 January 2018

Mechanisms of acquired crizotinib resistance in ALK-rearranged lung Cancers

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9391-7

21 January 2018

Effects of Src inhibitors on cell growth and epidermal growth factor receptor and MET signaling in gefitinib-resistant non-small cell lung cancer cells with acquired MET amplification

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9391-7

21 January 2018

The anti-proliferative effect of heat shock protein 90 inhibitor, 17-DMAG, on non-small-cell lung cancers being resistant to EGFR tyrosine kinase inhibitor

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9391-7

21 January 2018

Integrin beta1 over-expression associates with resistance to tyrosine kinase inhibitor gefitinib in non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9391-7

21 January 2018

Identifiers

10.1007/S10555-012-9391-7

1 reference

Europe PubMed Central

PubMed publication ID

27 August 2017

Dimensions Publication ID

0 references

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

27 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q38021967&oldid=1737882577"